Indivior Pharmaceuticals Inc(INDV)Earnings, Financials & Key RatiosIndivior Pharmaceuticals Inc (INDV) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company has successfully deleveraged its debt to $23.0 million, the persistent negative equity of $144.0 million and erratic cash conversion cycles warrant a cautious approach until operational profitability stabilizes.
Indivior Pharmaceuticals Inc (INDV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Indivior Pharmaceuticals Inc (INDV) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $0.96vs $0.64+50.0% | $317Mvs $273M+16.2% |
| Q1 2026 | Feb 26, 2026 | $0.82vs $0.65+26.2% | $358Mvs $306M+17.1% |
| Q4 2025 | Oct 30, 2025 | $0.72vs $0.38+89.5% | $314Mvs $306M+2.5% |
| Q3 2025 | Jul 31, 2025 | $0.51vs $0.26+96.2% | $302Mvs $255M+18.3% |
Recent stock market news and headlines for Indivior Pharmaceuticals Inc (INDV)
Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Key metrics vs top competitors for Indivior Pharmaceuticals Inc (INDV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $40.83 | $5.09B | 24.90 | 4.29% | 16.95% | — | — | |
| $2.12 | $372.28M | 9.64 | 1.28% | 3.8% | 7.85% | — | |
| $12.51 | $2.65B | 83.40 | 26.93% | 10.51% | 10.2% | — | |
| $15.55 | $1.65B | -2.27 | — | — | -866.46% | — | |
| $55.22 | $9.2B | 38.62 | -5.25% | 9.78% | 8.82% | — | |
| $4.91 | $1.83B | 11.42 | 8.53% | -11.27% | — | — |
Indivior Pharmaceuticals Inc (INDV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Indivior Pharmaceuticals Inc (INDV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Apr 30, 2026·SEC
Mar 17, 2026·SEC
Mar 13, 2026·SEC
Get notified when INDV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Indivior Pharmaceuticals Inc (INDV) stock FAQ — growth, dividends, profitability & financials explained
Indivior Pharmaceuticals Inc (INDV) reported $1.29B in revenue for fiscal year 2025. This represents a 33% increase from $968.9M in 2016.
Indivior Pharmaceuticals Inc (INDV) grew revenue by 4.3% over the past year. Growth has been modest.
Yes, Indivior Pharmaceuticals Inc (INDV) is profitable, generating $251.0M in net income for fiscal year 2025 (16.9% net margin).
Indivior Pharmaceuticals Inc (INDV) had negative free cash flow of $184.6M in fiscal year 2025, likely due to heavy capital investments.
